{
    "clinical_study": {
        "@rank": "50406", 
        "acronym": "RAVINE", 
        "brief_summary": {
            "textblock": "An evaluation of the incidence of complications resulting from far lateral spine surgery\n      utilizing the K2M RAVINE\u00ae Lateral Access System (RAVINE) with ALEUTIAN\u00ae Lateral Interbody\n      Spacer System versus literature reported results for the NuVasive XLIF\u00ae system (XLIF) in the\n      treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis."
        }, 
        "brief_title": "Comparison of Complication Rates Between Lateral Approaches to the Lumbar Spine", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Degenerative Disc Disease", 
            "Grade 1 Spondylolisthesis."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Spinal Diseases", 
                "Spondylolisthesis", 
                "Intervertebral Disk Degeneration"
            ]
        }, 
        "detailed_description": {
            "textblock": "An evaluation of the incidence of complications resulting from far lateral spine surgery\n      utilizing the K2M RAVINE\u00ae Lateral Access System (RAVINE) with ALEUTIAN\u00ae Lateral Interbody\n      Spacer System versus literature reported results for the NuVasive XLIF\u00ae system (XLIF) in the\n      treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at L2-S1\n      requiring surgical intervention at one or two contiguous levels. Safety will be assessed by\n      the following: 1.) Evaluation of all adverse events including device related, procedure\n      related and additional serious adverse events; 2.) Additional surgical intervention at the\n      operative site including the need for removals, revisions, re-operations or supplemental\n      fixation required to modify the device; and 3.) The incidence and severity of any psoas\n      muscle injury, genital femoral nerve injury and lumbar plexus injury will be determined for\n      all patients. Supplemental fixation of any kind may be included as long as the procedure is\n      completed via a minimally invasive approach."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of DDD with up to Grade 1 spondylolisthesis, confirmed clinically and\n             radiographically, requiring surgical intervention at one or two contiguous levels\n             between L2-S1\n\n          -  Inadequate response to conservative medical care over a period of at least 6 months\n\n          -  Willing and able to comply with the requirements of the protocol including follow-up\n             requirements\n\n          -  Willing and able to sign a study specific informed consent\n\n          -  Skeletally mature and \u2265 18 years of age at the time of enrollment\n\n        Exclusion Criteria:\n\n          -  Previous anterior/posterior/lateral spine surgery at the index level\n\n          -  Previous posterior/lateral spine surgery (e.g., posterior element decompression) that\n             destabilizes the lumbar spine\n\n          -  Active systemic infection or infection at the operative site\n\n          -  Co-morbid medical conditions of the spine or upper/lower extremities that may affect\n             the lumbar spine neurological and/or pain assessment\n\n          -  Metabolic bone disease such as osteoporosis that contradicts spinal surgery\n\n          -  History of an osteoporotic fracture\n\n          -  History of an endocrine or metabolic disorder (e.g., Paget's disease) known to affect\n             bone and mineral metabolism\n\n          -  Taking medications that may interfere with bony/soft tissue healing including chronic\n             steroid use\n\n          -  Known allergy to titanium, cobalt chrome or PEEK\n\n          -  Rheumatoid arthritis or other autoimmune disease or a systemic disorder such as HIV,\n             active hepatitis B or C or fibromyalgia\n\n          -  Insulin-dependent type 1 or type 2 diabetes\n\n          -  Current medical condition (e.g., unstable cardiac disease, cancer) that may result in\n             patient death or have an effect on outcomes prior to study completion\n\n          -  Pregnant, or intend to become pregnant, during the course of the study\n\n          -  Severe obesity (Body Mass Index > 40)\n\n          -  Physical or mental condition (e.g., psychiatric disorder, senile dementia,\n             Alzheimer's disease, alcohol or drug addiction) that would interfere with patient\n             self-assessment of function, pain or quality of life\n\n          -  Involved in current or pending spinal litigation where permanent disability benefits\n             are being sought\n\n          -  Incarcerated at the time of study enrollment\n\n          -  Current participation in an investigational study that may impact study outcomes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients eligible for study enrollment will have a primary diagnoses limited to\n        degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at L2-S1 requiring\n        surgical intervention at one or two contiguous levels. Qualified patients will have\n        confirmed failure of conservative therapy as well as plain film imaging studies.  Subjects\n        must be \u2265 18 years old at the time of enrollment."
            }
        }, 
        "enrollment": {
            "#text": "222", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068729", 
            "org_study_id": "CA-002"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "degenerative disc disease", 
            "DDD", 
            "Grade 1 spondylolisthesis", 
            "spondylolisthesis", 
            "L2-S1"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Comparison of Complication Rates Between Lateral Approaches to the Lumbar Spine: K2M RAVINE\u00ae Far Lateral System Versus NuVasive XLIF\u00ae", 
        "overall_contact": {
            "email": "jreigrut@k2m.com", 
            "last_name": "Julie L Reigrut, MS", 
            "phone": "3305180174"
        }, 
        "overall_contact_backup": {
            "email": "dtolbert@k2m.com", 
            "last_name": "Dawn Tolbert", 
            "phone": "7038401746"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluation of the improvement of the Back VAS and the Leg VAS at the 24 month post-operative visit as compared to pre-op time periods.  Information on all reports of pain/numbness/tingling and the location of symptoms will be captured and evaluated.", 
                "measure": "Back and Leg Visual Analog Scale (VAS) Change from Baseline", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "The evaluation of all adverse events including device related, procedure related and additional serious adverse events.", 
                "measure": "Number of Patients with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "reference": [
            {
                "PMID": "23213282", 
                "citation": "Malham GM, Ellis NJ, Parker RM, Seex KA. Clinical outcome and fusion rates after the first 30 extreme lateral interbody fusions. ScientificWorldJournal. 2012;2012:246989. doi: 10.1100/2012/246989. Epub 2012 Nov 1."
            }, 
            {
                "PMID": "23049476", 
                "citation": "Caputo AM, Michael KW, Chapman TM Jr, Massey GM, Howes CR, Isaacs RE, Brown CR. Clinical outcomes of extreme lateral interbody fusion in the treatment of adult degenerative scoliosis. ScientificWorldJournal. 2012;2012:680643. doi: 10.1100/2012/680643. Epub 2012 Sep 24."
            }, 
            {
                "PMID": "21160394", 
                "citation": "Youssef JA, McAfee PC, Patty CA, Raley E, DeBauche S, Shucosky E, Chotikul L. Minimally invasive surgery: lateral approach interbody fusion: results and review. Spine (Phila Pa 1976). 2010 Dec 15;35(26 Suppl):S302-11. doi: 10.1097/BRS.0b013e3182023438."
            }, 
            {
                "PMID": "22402840", 
                "citation": "Berjano P, Balsano M, Buric J, Petruzzi M, Lamartina C. Direct lateral access lumbar and thoracolumbar fusion: preliminary results. Eur Spine J. 2012 May;21 Suppl 1:S37-42. doi: 10.1007/s00586-012-2217-z. Epub 2012 Mar 9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068729"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "An independent neurological evaluation of the patient, with specific evaluation of psoas muscle weakness, radiating radicular pain, knee extension weakness, dorsiflexion weakness, plantarflexion weakness and anterior thigh numbness will be performed.", 
                "measure": "Change in Incidence of Thigh Pain/Dysesthesia", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 8 weeks post-operatively, 3 months, 6 months, 12 months, and 24 months"
            }, 
            {
                "description": "The Oswestry Disability Index (ODI) is a validated instrument including items that relate to subjective symptomatology and activities of daily living (pain intensity, personal care, lifting, walking, sitting, standing, sex life, traveling). Each item is scored from 0 up to 5, with higher scores corresponding to greater disability.  A total ODI score is determined by adding the scores of the individual questions and dividing that total by the maximum possible score (i.e., 50 if all questions are answered) to yield a percentage. Therefore, the ODI score ranges from 0% to 100%.  An improvement by at least 15 percentage points will be considered a success.", 
                "measure": "Change in Oswestry Disability Index", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 8 weeks post-operatively, 3 months, 6 months, 12 months, and 24 months"
            }, 
            {
                "description": "Health-related quality of life will be evaluated in all study subjects using the SF-12v2 Health Survey. This shortened and simplified version of the SF-36 makes the questionnaire less ambiguous for patients. It has a self-administered form that makes it easy to read and complete, and that reduces missing responses. The physical and mental component summary scales, referred to as PCS-12 and MCS-12 will be evaluated against published normative values and a 15% improvement in these scores will be used as an assessment of success. To calculate the true value of a treatment, the scores from the SF-12v2 will be converted into a utility index (SF-6D), which considers not only how many years a medical intervention can add to a patient's life, but also the quality of that life. Use of the SF-6D does not expand the questions administered to the patient.", 
                "measure": "Change in Health-Related Quality of Life from Baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 8 weeks post-operatively, 3 months, 6 months, 12 months, and 24 months"
            }, 
            {
                "description": "Quantitative and qualitative radiographic assessment of the pre and post-operative AP, and Lateral, Flexion/Extension images will be performed. Radiographic assessments being performed include:\nQualitative Assessment\nDevice Condition\nDevice Subsidence\nDevice Migration\nRadiographic Assessment of Fusion/Non-fusion\nBony Bridging\nRadiolucency\nDevelopment of Pseudoarthrosis", 
                "measure": "Radiographic Assessments", 
                "safety_issue": "No", 
                "time_frame": "AP & Lateral: pre-operatively, 6 months post-operatively, 12 months post-operatively, 24 months post-operatively; Flexion/Extension:12 months post-operatively, 24 months post-operatively"
            }, 
            {
                "description": "At the 12 month and 24 month follow-up visits, subjects will be asked whether they were satisfied with the outcome of their surgery (Yes/No) and whether they would repeat the operation (Yes/No).", 
                "measure": "Patient Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "12 month and 24 month follow-up visits"
            }, 
            {
                "description": "At the 24 month follow-up visit, the Investigator will rate the clinical disposition of each study subject according to Odom's Criteria as follows:\nExcellent: all pre-operative symptoms relieved, able to carry out daily occupations without impairment.\nGood: minimum persistence of pre-operative symptoms, able to carry out daily occupations without significant interference.\nFair/Satisfactory: relief of some pre-operative symptoms but physical activity is significantly limited.\nPoor: symptoms or signs unchanged or worse.", 
                "measure": "Odom's Criteria", 
                "safety_issue": "No", 
                "time_frame": "24 months post-operatively"
            }, 
            {
                "description": "The length of the surgical procedure from the initial incision to final closure will be captured from the Anesthesia Record.", 
                "measure": "Surgery Time", 
                "safety_issue": "No", 
                "time_frame": "During operation."
            }, 
            {
                "description": "The length of time the patient is under anesthesia will be captured from the Anesthesia Record.", 
                "measure": "Anesthesia Time", 
                "safety_issue": "No", 
                "time_frame": "During operation."
            }, 
            {
                "description": "The amount of blood loss over the entire length of the surgery, documented on the Anesthesia Record, will be captured.", 
                "measure": "Estimated Blood Loss", 
                "safety_issue": "Yes", 
                "time_frame": "During Operation"
            }, 
            {
                "description": "The type(s) and any abnormal result(s) of neuromonitoring systems utilized during the surgery will be captured.", 
                "measure": "Neuromonitoring", 
                "safety_issue": "No", 
                "time_frame": "During operation"
            }, 
            {
                "description": "The length of hospital stay from the date of hospital admission to the date of discharge will be calculated.", 
                "measure": "Length of Hospital Stay", 
                "safety_issue": "No", 
                "time_frame": "At discharge, estimated average of 2 days post-surgery."
            }, 
            {
                "description": "The ability to and the time it takes for the subject to be cleared to return to work/school from the date of surgery will be documented.", 
                "measure": "Change in Work/School Status compared to Baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks post-operatively, 3 months, 6 months, 12 months, and 24 months"
            }, 
            {
                "description": "The types and dosages of any narcotics taken by the patient post-surgery will be documented.", 
                "measure": "Change in Use of Narcotics Post-Surgery Compared to Baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks post-operatively, 3 months, 6 months, 12 months, and 24 months"
            }
        ], 
        "source": "K2M, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "K2M, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}